Synageva posts positive top-line data for enzyme replacement therapy
Rare disease specialist Synageva Biopharma Corp. reported top-line phase III data showing that sebelipase alfa, its enzyme replacement therapy for LAL deficiency, met its primary endpoint and several secondary endpoints.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter